Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

Nephrol Dial Transplant. 2006 Oct;21(10):2696-702. doi: 10.1093/ndt/gfl448. Epub 2006 Jul 31.

Authors

Henri Boulanger¹, Rafik Mansouri, Jean François Gautier, Denis Glotz

Affiliation

¹ Department of Nephrology and Transplantation, Saint-Louis Hospital, 1 avenue Claude-Vellefaux, 75475 Paris Cedex 10, France. [email protected]

PMID: 16880183
DOI: 10.1093/ndt/gfl448

No abstract available

Publication types

Review

MeSH terms

Animals
Blood Pressure / drug effects
Diabetic Nephropathies / blood
Diabetic Nephropathies / drug therapy*
Diabetic Nephropathies / physiopathology
Disease Models, Animal
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Kidney Diseases / blood
Kidney Diseases / drug therapy*
Kidney Diseases / physiopathology
Peroxisome Proliferator-Activated Receptors / agonists*
Peroxisome Proliferator-Activated Receptors / blood
Thiazolidinediones / pharmacology
Thiazolidinediones / therapeutic use

Substances

Hypoglycemic Agents
Peroxisome Proliferator-Activated Receptors
Thiazolidinediones